Published on 20 Jun 2024 on Simply Wall St. · via Yahoo Finance

AC Immune SA (NASDAQ:ACIU): Are Analysts Optimistic?

AC Immune SA (NASDAQ:ACIU) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s loss has recently broadened since it announced a CHF54m loss in the full financial year, compared to the latest trailing-twelve-month loss of CHF55m, moving it further away from breakeven. As path to profitability is the topic on AC Immune's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

View our latest analysis for AC Immune